Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 14, Pages -Publisher
MDPI
DOI: 10.3390/ijms22147398
Keywords
MBC; metaplastic breast carcinoma; EMT; epithelial-mesenchymal transition immune system
Funding
- Instituto de Salud Carlos III (ISCIII) [PI19/01331]
- CIBERONC [CB16/12/00316, CB16/12/00449]
- European Development Regional Fund. 'A way to achieve Europe' (FEDER)
- Spanish Association Against Cancer Scientific Foundation
Ask authors/readers for more resources
Metaplastic breast carcinoma (MBC) is a rare triple negative invasive cancer with poor prognosis. The resistance mechanisms of MBC may involve epithelial-mesenchymal transition (EMT) and immune response, distinguishing it from other types of breast cancer.
Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example of tumors with activation of epithelial-mesenchymal transition (EMT). The mechanisms involved in EMT could be responsible for the increase in the infiltrative and metastatic capacity of MBCs and resistance to treatments. In addition, a relationship between EMT and the immune response has been seen in these tumors. In this sense, MBC differ from other TN tumors showing a lower number of tumor-infiltrating lymphocytes (TILS) and a higher percentage of tumor cells expressing programmed death-ligand 1 (PD-L1). A better understanding of the relationship between the immune system and EMT could provide new therapeutic approaches in MBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available